← All trials
NCT01237639
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2011
- Primary completion
- Oct 31, 2016
- Completion date
- Oct 31, 2016
- First posted
- Nov 9, 2010
- Last posted
- Oct 12, 2016
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OttawaLead sponsor
- Canadian Blood ServicesCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Hamilton Health Sciences CorporationCollaborator
- University of Western OntarioCollaborator
- University of OttawaOverall official - principal investigator
- University of OttawaCollaborator
- University of OttawaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.